Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What the guidelines do not say: statin non-benefit groups.

Pamela B Morris1, Kellie McLain

  • 1Medical University of South Carolina, 25 Courtenay Drive, MSC 592, Charleston, SC, 29425, USA, morrispa@musc.edu.

Current Atherosclerosis Reports
|November 19, 2014
PubMed
Summary

The 2013 guidelines identify four statin benefit groups for atherosclerotic cardiovascular disease (ASCVD) risk reduction. Clinicians must consider evidence limitations for patients outside these groups to personalize statin therapy decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.

Journal of the American College of Cardiology·2026
Same author

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.

Circulation·2026
Same author

Dyslipidemia Guideline Development: Building on a Robust Foundation.

Journal of the American College of Cardiology·2026
Same author

Building Global Bridges in Clinical Guidance: Harmony Across Dyslipidemia Guidelines.

Journal of the American College of Cardiology·2026
Same author

2026 Dyslipidemia Guideline-at-a-Glance.

Journal of the American College of Cardiology·2026

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • The 2013 ACC/AHA guidelines define four primary groups of adults (40-75 years) who benefit from statin therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk.
  • These groups include individuals with clinical ASCVD, diabetes, LDL-C >190 mg/dl, or a 10-year ASCVD risk ≥7.5% via the Cardiovascular Risk Calculator.

Purpose of the Study:

  • To address the challenge clinicians face with patients who do not clearly fit into the established statin-benefit groups.
  • To guide personalized decision-making and inform patient discussions about statin therapy risks and benefits for those outside the primary benefit groups.

Main Methods:

  • Review and synthesis of existing evidence and guidelines pertaining to statin therapy.
  • Analysis of the limitations of current guidelines for specific patient populations.

Related Experiment Videos

  • Emphasis on shared decision-making between clinicians and patients.

    • Main Results:

    • The established guidelines provide clear recommendations for four specific statin-benefit groups.
    • A significant number of patients do not neatly fall into these defined categories, requiring nuanced clinical judgment.
    • Understanding guideline limitations is crucial for appropriate statin use in broader patient populations.

    Conclusions:

    • Personalized patient care requires considering factors beyond the four primary statin-benefit groups.
    • Clinicians need to be aware of the evidence gaps and additional guidelines for statin non-benefit groups.
    • Informed clinician-patient discussions are essential for optimizing statin therapy decisions and managing ASCVD risk.